BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Δ⁹-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells.
Authors: Jessica M. Sido, Prakash S. Nagarkatti, Mitzi Nagarkatti
Journal of Leukocyte Biology, September 2015
—
Immune cells have been shown to express cannabinoid receptors and to produce endogenous ligands. Moreover, activation of cannabinoid receptors on immune cells has been shown to trigger potent immunosuppression. Despite such studies, the role of cannabinoids in transplantation…
Cannabinoids for the Treatment of Movement Disorders.
Authors: Briony Catlow, Juan Sanchez-Ramos
Current Treatment Options in Neurology, September 2015
—
Use of cannabinoids as medications has a long history. Unfortunately, the prohibition of cannabis and its classification in 1970 as a schedule 1 drug has been a major obstacle in studying these agents in a systematic, controlled manner. The number of class 1 studies (randomize…
The psychoactive compound of Cannabis sativa, Δ(9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover.
Authors: M.A. Costa, B.M. Fonseca, F. Marques, N.A. Teixeira, G. Correia-da-Silva
Toxicology, 6 August 2015
—
The noxious effects of cannabis consumption for fertility and pregnancy outcome are recognized for years. Its consumption during gestation is associated with alterations in foetal growth, low birth weight and preterm labor. The main psychoactive molecule of cannabis, Δ(9)-tetr…
Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.
Authors: Alexandra L. Geffrey, Sarah F. Pollack, Patricia L. Bruno, Elizabeth A. Thiele
Epilepsia, August 2015
—
OBJECTIVE: Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children. Of the 25 subjects in the trial, 13 were being treated with clobazam (CLB). Because CLB and CBD are…
Use and effects of cannabinoids in military veterans with posttraumatic stress disorder.
Authors: Kevin Betthauser, Jeffrey Pilz, Laura E. Vollmer
American Journal of Health-System Pharmacy, 1 August 2015
—
PURPOSE: Published evidence regarding the use of cannabis and cannabis derivatives by military veterans with posttraumatic stress disorder (PTSD) is reviewed. SUMMARY: When inhaled or delivered orally or transdermally, cannabinoids (the psychoactive components of unrefined mar…
Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy.
Authors: Mark S. Wallace, Thomas D. Marcotte, Anya Umlauf, Ben Gouaux, Joseph H. Atkinson
The Journal of Pain, July 2015
—
A randomized, double-blinded, placebo controlled crossover study was conducted in 16 patients with painful diabetic peripheral neuropathy to assess the short-term efficacy and tolerability of inhaled cannabis. In a crossover design, each participant was exposed to 4 single dos…
Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys.
Authors: Deborah S. Hasin, Melanie Wall, Katherine M. Keyes, Magdalena Cerdá, John Schulenberg, et al
The Lancet Psychiatry, July 2015
—
BACKGROUND: Adolescent use of marijuana is associated with adverse later effects, so the identification of factors underlying adolescent use is of substantial public health importance. The relationship between US state laws that permit marijuana for medical purposes and adoles…
Psychotic experiences are linked to cannabis use in adolescents in the community because of common underlying environmental risk factors.
Authors: Sania Shakoor, Helena M.S. Zavos, Philip McGuire, Alastair G. Cardno, et al
Psychiatry Research, 30 June 2015
—
Cannabis users are more likely to have psychotic experiences (PEs). The degree to which these associations are driven by genetic or environmental influences in adolescence is unknown. This study estimated the genetic and environmental contributions to the relationship between…
Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products.
Authors: Ryan Vandrey, Jeffrey C. Raber, Mark E. Raber, Brad Douglass, Cameron Miller, Marcel O. Bonn-Miller
JAMA, 23 June 2015
—
As the use of cannabis (marijuana) for medical purposes has expanded, a variety of edible products for oral consumption has been developed. An estimated 16% to 26% of patients using medical cannabis consume edible products.1,2 Even though oral consumption lacks the harmful by-…
Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.
Authors: Kevin P. Hill
JAMA, 23 June 2015
—
IMPORTANCE: As of March 2015, 23 states and the District of Columbia had medical marijuana laws in place. Physicians should know both the scientific rationale and the practical implications for medical marijuana laws. OBJECTIVE: To review the pharmacology, indications, and law…
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
Authors: Penny F. Whiting, Robert F. Wolff, Sohan Deshpande, Marcello Di Nisio, Steven Duffy, et al
JAMA, 23 June 2015
—
IMPORTANCE: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty…
Medical Marijuana: Is the Cart Before the Horse?
Authors: Deepak Cyril D’Souza, Mohini Ranganathan
JAMA, 23 June 2015
—
There is a pressing need to develop new medications for many debilitating conditions. Novel approaches based on marijuana or its constituent cannabinoids, if proven, could be added to the armamentarium of available treatments. In this issue of JAMA, reviews by Whiting et al1 a…